Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy

Seth E. Karol; Elaine Coustan-Smith; Xueyuan Cao; Sheila A. Shurtleff; Susana C. Raimondi; John K. Choi; Raul C. Ribeiro; Gary V. Dahl; William Paul Bowman; Jeffrey W. Taub; Barbara Degar; Wing Leung; James R. Downing; Ching Hon Pui; Jeffrey E. Rubnitz; Dario Campana; Hiroto Inaba

doi:10.1111/bjh.13107

Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy

Seth E. Karol, Elaine Coustan-Smith, Xueyuan Cao, Sheila A. Shurtleff, Susana C. Raimondi, John K. Choi, Raul C. Ribeiro, Gary V. Dahl, William Paul Bowman, Jeffrey W. Taub, Barbara Degar, Wing Leung, James R. Downing, Ching Hon Pui, Jeffrey E. Rubnitz, Dario Campana, Hiroto Inaba

Pediatrics

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Minimal residual disease (MRD) is a strong prognostic factor in children and adolescents with acute myeloid leukaemia (AML) but nearly one-quarter of patients who achieve MRD-negative status still relapse. The adverse prognostic factors among MRD-negative patients remain unknown. We analysed the AML02 study cohort to identify demographic and genetic prognostic factors. Among the presenting features, certain 11q23 abnormalities, such as t(6;11) and t(10;11), acute megakaryoblastic leukaemia without the t(1;22), and age ≥10 years were associated with inferior outcome in patients who had MRD-negative status after either remission induction I or II. By contrast, those with rearrangement of CBF genes had superior outcome. Our study identifies patient populations for whom close post-remission MRD monitoring to detect and treat emerging relapse and adjustment in treatment intensity might be indicated.

Original language	English
Pages (from-to)	94-101
Number of pages	8
Journal	British Journal of Haematology
Volume	168
Issue number	1
DOIs	https://doi.org/10.1111/bjh.13107
State	Published - 1 Jan 2015

Keywords

Acute myeloid leukaemia
Minimal residual disease
Paediatric
Prognostic factor

Access to Document

10.1111/bjh.13107

Cite this

Karol, S. E., Coustan-Smith, E., Cao, X., Shurtleff, S. A., Raimondi, S. C., Choi, J. K., Ribeiro, R. C., Dahl, G. V., Bowman, W. P., Taub, J. W., Degar, B., Leung, W., Downing, J. R., Pui, C. H., Rubnitz, J. E., Campana, D., & Inaba, H. (2015). Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. British Journal of Haematology, 168(1), 94-101. https://doi.org/10.1111/bjh.13107

@article{1738070b6bd14b6ab5e8582bf11a8b10,

title = "Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy",

abstract = "Minimal residual disease (MRD) is a strong prognostic factor in children and adolescents with acute myeloid leukaemia (AML) but nearly one-quarter of patients who achieve MRD-negative status still relapse. The adverse prognostic factors among MRD-negative patients remain unknown. We analysed the AML02 study cohort to identify demographic and genetic prognostic factors. Among the presenting features, certain 11q23 abnormalities, such as t(6;11) and t(10;11), acute megakaryoblastic leukaemia without the t(1;22), and age ≥10 years were associated with inferior outcome in patients who had MRD-negative status after either remission induction I or II. By contrast, those with rearrangement of CBF genes had superior outcome. Our study identifies patient populations for whom close post-remission MRD monitoring to detect and treat emerging relapse and adjustment in treatment intensity might be indicated.",

keywords = "Acute myeloid leukaemia, Minimal residual disease, Paediatric, Prognostic factor",

author = "Karol, {Seth E.} and Elaine Coustan-Smith and Xueyuan Cao and Shurtleff, {Sheila A.} and Raimondi, {Susana C.} and Choi, {John K.} and Ribeiro, {Raul C.} and Dahl, {Gary V.} and Bowman, {William Paul} and Taub, {Jeffrey W.} and Barbara Degar and Wing Leung and Downing, {James R.} and Pui, {Ching Hon} and Rubnitz, {Jeffrey E.} and Dario Campana and Hiroto Inaba",

note = "Publisher Copyright: {\textcopyright} 2014 John Wiley & Sons Ltd.",

year = "2015",

month = jan,

day = "1",

doi = "10.1111/bjh.13107",

language = "English",

volume = "168",

pages = "94--101",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

Karol, SE, Coustan-Smith, E, Cao, X, Shurtleff, SA, Raimondi, SC, Choi, JK, Ribeiro, RC, Dahl, GV, Bowman, WP, Taub, JW, Degar, B, Leung, W, Downing, JR, Pui, CH, Rubnitz, JE, Campana, D & Inaba, H 2015, 'Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy', British Journal of Haematology, vol. 168, no. 1, pp. 94-101. https://doi.org/10.1111/bjh.13107

TY - JOUR

T1 - Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy

AU - Karol, Seth E.

AU - Coustan-Smith, Elaine

AU - Cao, Xueyuan

AU - Shurtleff, Sheila A.

AU - Raimondi, Susana C.

AU - Choi, John K.

AU - Ribeiro, Raul C.

AU - Dahl, Gary V.

AU - Bowman, William Paul

AU - Taub, Jeffrey W.

AU - Degar, Barbara

AU - Leung, Wing

AU - Downing, James R.

AU - Pui, Ching Hon

AU - Rubnitz, Jeffrey E.

AU - Campana, Dario

AU - Inaba, Hiroto

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Minimal residual disease (MRD) is a strong prognostic factor in children and adolescents with acute myeloid leukaemia (AML) but nearly one-quarter of patients who achieve MRD-negative status still relapse. The adverse prognostic factors among MRD-negative patients remain unknown. We analysed the AML02 study cohort to identify demographic and genetic prognostic factors. Among the presenting features, certain 11q23 abnormalities, such as t(6;11) and t(10;11), acute megakaryoblastic leukaemia without the t(1;22), and age ≥10 years were associated with inferior outcome in patients who had MRD-negative status after either remission induction I or II. By contrast, those with rearrangement of CBF genes had superior outcome. Our study identifies patient populations for whom close post-remission MRD monitoring to detect and treat emerging relapse and adjustment in treatment intensity might be indicated.

AB - Minimal residual disease (MRD) is a strong prognostic factor in children and adolescents with acute myeloid leukaemia (AML) but nearly one-quarter of patients who achieve MRD-negative status still relapse. The adverse prognostic factors among MRD-negative patients remain unknown. We analysed the AML02 study cohort to identify demographic and genetic prognostic factors. Among the presenting features, certain 11q23 abnormalities, such as t(6;11) and t(10;11), acute megakaryoblastic leukaemia without the t(1;22), and age ≥10 years were associated with inferior outcome in patients who had MRD-negative status after either remission induction I or II. By contrast, those with rearrangement of CBF genes had superior outcome. Our study identifies patient populations for whom close post-remission MRD monitoring to detect and treat emerging relapse and adjustment in treatment intensity might be indicated.

KW - Acute myeloid leukaemia

KW - Minimal residual disease

KW - Paediatric

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=84915737335&partnerID=8YFLogxK

U2 - 10.1111/bjh.13107

DO - 10.1111/bjh.13107

M3 - Article

C2 - 25164427

AN - SCOPUS:84915737335

SN - 0007-1048

VL - 168

SP - 94

EP - 101

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this